Prophylactic Cervical Cerclage in Twin Pregnancies With Non-shortened Cervix

Sponsor
Zagazig University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05334264
Collaborator
(none)
170
1
2
11.8
14.4

Study Details

Study Description

Brief Summary

This randomized controlled trial is aimed to assess the protective value of prophylactic cervical cerclage against preterm birth in twin pregnancies with history of one or more preterm births without having cervical shortening in the current pregnancy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Cervical cerclage
N/A

Detailed Description

Multiple pregnancies are high-risk pregnancies and usually associated with an increased risk of neonatal morbidity and mortality, mainly due to preterm births. Preterm births occur in 50% of twin pregnancies and the mean gestational age for delivery is 35.3 weeks. Ten percent of all twin births take place before 32 weeks of gestation.1 Preterm births are responsible for more than 70% of all neonatal and infant deaths.2 Prematurity can have serious consequences for the child, such as hearing difficulties, vision impairment, learning disabilities, reduced IQ, and cerebral palsy. A cervical length of ≤25 mm in twin pregnancies is a good predictor of a spontaneous preterm birth when measured around 24 weeks of gestation.3,4 Numerous interventions have been attempted in order to prevent preterm births in twin gestations, but until now, no intervention has been effective. Use of cerclage in twin pregnancies is controversial. Some experts claim that placing a cervical cerclage could increase the risk of preterm births5, Fuchs and Senat6 concluded that cervical cerclage in asymptomatic twins did not reduce the risk of PTB. This conclusion came depending on small sample sized randomized trail done on less than 50 patients.7 Available meta-analytic data remained of limited value in view of the few and small clinical studies that were included.

Although the current meta-analyses indicate the lack of efficacy of cerclage in twin pregnancies, data from the US Standard Certificate of Live Birth indicated that roughly 10% of triplets and 1.3% of twins are still receiving cerclage.8 Some authors compared the efficacy of cerclage in twin pregnancies and singleton pregnancies and showed that women with twin pregnancies who received cerclage might show beneficial obstetric outcomes similar to those of women with singleton gestations.9,10 Such practice is still in need for further validation by well-structured and powered randomized controlled trials.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
170 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Value of Prophylactic Cervical Cerclage Against Preterm Birth in Twin Pregnancies With History of Preterm Birth and Non-shortened Cervix: A Randomized Controlled Trial
Actual Study Start Date :
Dec 20, 2021
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Dec 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A

cervical cerclage between 14 and 20 weeks will be done by one of the three authors. McDonald cervical cerclage.

Procedure: Cervical cerclage
McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.

No Intervention: Group B

Routine antenatal care without cerclage

Outcome Measures

Primary Outcome Measures

  1. The incidence of preterm birth at ≤35+6, ≤33+6, and ≤31+6 weeks. [immediately after delivery for study cases through study completion, an average of 1 year]

    Number of preterm deliveries stratified according to gestational age groups mentioned

Secondary Outcome Measures

  1. The incidence of miscarriage. [immediately after occurrence of miscarriage through study completion, an average of 1 year]

    Number of missed, inevitable and complete miscarriage less than 20 weeks

  2. Incidence of cervico-vaginal infection [once reported or confirmed during pregnancy through study completion, an average of 1 year]

    Number of infections diagnosed by patient complaint, clinical examination and confirmed by culture and sensitivity

  3. Incidences of bad Neonatal outcomes in both groups [during early neonatal follow up through study completion, an average of 1 year]

    Number of of neonates with respiratory distress, IVH, necrotizing enterocolitis, sepsis, NICU admission

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age between 18-50 years.

  • Dichorionic twins.

  • History of ≥1 preterm birth.

  • Transvaginal sonographic cervical length is ≥25 mm at 14-20 weeks gestational age.

  • Asymptomatic.

Exclusion Criteria:
  • Triplets and quadruplets.

  • Monochorionic twins.

  • Threatened/ inevitable miscarriage

  • Bulging membranes through the external os.

  • Extremes of age.

  • Major fetal anomalies.

  • Known cases with uterine anomalies e.g. bicornuate uterus, uterus didelphis… etc.

  • Fetal demise.

  • Fetal reduction in the current pregnancy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of medicine, Zagazig University Zagazig Sharkia Egypt 44519

Sponsors and Collaborators

  • Zagazig University

Investigators

  • Principal Investigator: Amro El Nemr, Zagazig University
  • Principal Investigator: Mohamed Lashin, Zagazig University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hytham Atia, Associate professor, Zagazig University
ClinicalTrials.gov Identifier:
NCT05334264
Other Study ID Numbers:
  • ZU-IRB #8084/17-10-2021
First Posted:
Apr 19, 2022
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022